---
title: "U.S. stock market update: Humana down 7.44%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256613531.md"
description: "Humana fell 7.44%; UnitedHealth rose 8.87%, with a transaction volume of $11.3 billion; Cigna rose 6.15%, with a transaction volume of $371 million; Elevance Health rose 2.19%, with a transaction volume of $285 million; Molina Healthcare rose 2.33%, with a market value of $9.752 billion"
datetime: "2025-09-09T18:12:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256613531.md)
  - [en](https://longbridge.com/en/news/256613531.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256613531.md)
generator: "portal-rs"
---

# U.S. stock market update: Humana down 7.44%

**U.S. Stock Market Midday Update**

**Stocks with High Trading Volume in the Industry**

UnitedHealth rose 8.87%, with a trading volume of $11.3 billion. Based on recent important news:

1.  On September 9, UnitedHealth reaffirmed its 2025 earnings guidance and announced positive rating results for its Medicare plans, causing the stock price to rise by 4.2%. The company expects that by 2027, approximately 78% of members will enroll in plans rated four stars or higher, boosting market confidence.

2.  On September 9, Truist Securities raised UnitedHealth's target price from $310 to $365, reflecting analysts' confidence in the company's future growth.

3.  On September 8, UnitedHealth confirmed its adjusted earnings per share expectations for 2025 and reiterated its financial guidance ahead of an investor meeting, leading to a 2.3% increase in stock price. The Medicare industry faces cost pressures and policy change risks.

Centene rose 6.15%, with increased trading volume. According to recent key news:

1.  On September 9, Cantor Fitzgerald analysts downgraded Centene's rating to Neutral, with a target price of $38. This move weakened market confidence in Centene, leading to increased stock price volatility.

2.  On September 8, Centene faced multiple securities class action lawsuits, raising investor concerns about the company's future performance, which affected stock performance.

3.  On September 7, Rosen Law Firm reminded investors to participate in the class action lawsuit before the September 8 deadline, increasing market uncertainty. The market reacted strongly to the legal litigation risks.

Elevance Health rose 2.19%. Based on recent important news:

1.  On September 8, Elevance Health submitted a pricing term sheet for a four-part note issuance of up to $3 billion. This move was seen by the market as an enhancement of the company's financing capabilities, driving the stock price up. Data source: U.S. Securities and Exchange Commission filings.

2.  On September 8, Elevance Health's stock price rose 1.3% in early trading, benefiting from the overall positive performance of the Medicare industry. Data source: Reuters.

3.  On September 8, Elevance Health confirmed its adjusted profit expectation for 2025 to be at least $16 per share, enhancing investor confidence. Data source: Company announcement

### Related Stocks

- [HUM.US](https://longbridge.com/en/quote/HUM.US.md)

## Related News & Research

- [Humana is dumping 600,000 Medicare Advantage members in 2027 -- 7 moves to make if you're one of them](https://longbridge.com/en/news/298806586.md)
- [15:11 ETDid Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?](https://longbridge.com/en/news/298230971.md)
- [3,146 Shares in Humana Inc. $HUM Bought by Retireful LLC](https://longbridge.com/en/news/297898101.md)
- [Humana (NYSE:HUM) Releases FY 2026 Earnings Guidance](https://longbridge.com/en/news/297667325.md)
- [Ambea publishes offer document, prospectus for Humana takeover bid](https://longbridge.com/en/news/296795928.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**